<p>Full-length Gag-Protease sequences from pre-PI therapy and failure time-points was amplified or synthesised, and single round phenotypic susceptibility testing performed. PIs tested were Lopinavir (LPV) and Darunavir (DRV). (A) Susceptibility data from patient 5 demonstrates the reduction in susceptibility conferred by major mutations I84V (black) and I54V (grey) in our system in comparison with the patient virus at pre-PI therapy (white). Error bars represent standard deviation of two independent experimental repeats. (B) Virus derived pre-PI therapy (white bar) and at time of failure (black bar) from patient 6 demonstrated a difference in susceptibility to LPV in the absence of the development of major resistance mutations.</p
Virological failure (VF) to boosted PIs with a high genetic barrier is not usually linked to the dev...
HIV Gag mutations have been reported to confer PI drug resistance. However, clinical implications ar...
Several groups have proposed that genotypic determinants in gag and the gp41 cytoplasmic domain (gp4...
<p>Full-length Gag-Protease from pre-PI therapy and failure time-points was amplified or synthesised...
Major protease mutations are rarely observed following failure with protease inhibitors (PI), and ot...
OBJECTIVES: Major protease mutations are rarely observed following first-line failure with PIs and i...
Background: Major protease mutations are rarely observed following failure with protease inhibitors ...
Background Major protease mutations are rarely observed following failure with protease inhibitors (...
BACKGROUND: Major protease mutations are rarely observed following failure with protease inhibitors ...
BACKGROUND: Virological failure of first-line antiretroviral therapy based on lopinavir boosted with...
Around 2.5 million HIV-infected individuals failing first-line therapy qualify for boosted protease ...
Recent reports have shown that HIV-1 Gag can directly affect susceptibility to protease inhibitors (...
The development of antiretroviral (ARV) drugs and their use in human immunodeficiency virus type 1 (...
Protease inhibitors (PIs) are the second- and last-line therapy for the majority of HIV-infected pat...
<p>250 samples from 234 drug-naive patients and 115 samples from 78 treated A/AE patients were genot...
Virological failure (VF) to boosted PIs with a high genetic barrier is not usually linked to the dev...
HIV Gag mutations have been reported to confer PI drug resistance. However, clinical implications ar...
Several groups have proposed that genotypic determinants in gag and the gp41 cytoplasmic domain (gp4...
<p>Full-length Gag-Protease from pre-PI therapy and failure time-points was amplified or synthesised...
Major protease mutations are rarely observed following failure with protease inhibitors (PI), and ot...
OBJECTIVES: Major protease mutations are rarely observed following first-line failure with PIs and i...
Background: Major protease mutations are rarely observed following failure with protease inhibitors ...
Background Major protease mutations are rarely observed following failure with protease inhibitors (...
BACKGROUND: Major protease mutations are rarely observed following failure with protease inhibitors ...
BACKGROUND: Virological failure of first-line antiretroviral therapy based on lopinavir boosted with...
Around 2.5 million HIV-infected individuals failing first-line therapy qualify for boosted protease ...
Recent reports have shown that HIV-1 Gag can directly affect susceptibility to protease inhibitors (...
The development of antiretroviral (ARV) drugs and their use in human immunodeficiency virus type 1 (...
Protease inhibitors (PIs) are the second- and last-line therapy for the majority of HIV-infected pat...
<p>250 samples from 234 drug-naive patients and 115 samples from 78 treated A/AE patients were genot...
Virological failure (VF) to boosted PIs with a high genetic barrier is not usually linked to the dev...
HIV Gag mutations have been reported to confer PI drug resistance. However, clinical implications ar...
Several groups have proposed that genotypic determinants in gag and the gp41 cytoplasmic domain (gp4...